Comparative efficacy of tulathromycin and tildipirosin for the treatment of experimental Mycoplasma bovis infection in calves
The objective of this negative controlled, blinded, randomised, parallel group study was to compare the efficacy of two injectable macrolide antimicrobials, tulathromycin and tildipirosin, administered by single subcutaneous injection at dose rates of 2.5 and 4.0 mg kg−1 bodyweight, respectively, in...
Gespeichert in:
| Veröffentlicht in: | Veterinary medicine and science 2016-08, Vol.2 (3), p.170-178 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 178 |
|---|---|
| container_issue | 3 |
| container_start_page | 170 |
| container_title | Veterinary medicine and science |
| container_volume | 2 |
| creator | Bartram, David J. Moyaert, Hilde Vanimisetti, Bindu H. Ramage, Clifford P. Reddick, David Stegemann, Michael R. |
| description | The objective of this negative controlled, blinded, randomised, parallel group study was to compare the efficacy of two injectable macrolide antimicrobials, tulathromycin and tildipirosin, administered by single subcutaneous injection at dose rates of 2.5 and 4.0 mg kg−1 bodyweight, respectively, in the treatment of an experimentally induced Mycoplasma bovis infection in calves. A total of 238 M. bovis‐negative calves were challenged on three consecutive days with M. bovis by endobronchial deposition. Post‐challenge, a total of 126 animals fulfilled the inclusion criteria and were randomly allocated to three treatment groups: tulathromycin, tildipirosin and saline. Clinical observations for signs of respiratory disease and injection site assessments were conducted daily for 14 days post‐treatment. The animals were then killed, the lungs were examined for evidence of lesions, and samples collected for bacterial isolation. Calves treated with tulathromycin had a lower percentage of lung with lesions (P = 0.0079), lower mortality (P = 0.0477), fewer days with depressed demeanour (P = 0.0486) and higher body weight (P = 0.0112) than calves administered tildipirosin.
The objective of this negative controlled, blinded, randomised, parallel group study was to compare the efficacy of two injectable macrolide antibiotics, tulathromycin and tildipirosin, administered by single subcutaneous injection at dose rates of 2.5 and 4.0 mg kg−1 bodyweight, respectively, in the treatment of an experimentally induced Mycoplasma bovis infection in calves. Calves treated with tulathromycin had a lower percentage of lung with lesions, (P = 0.0079), lower mortality (P = 0.0477), fewer days with depressed demeanour (P = 0.0486) and higher body weight (P = 0.0112) than cattle administered tildipirosin. |
| doi_str_mv | 10.1002/vms3.31 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5645867</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1955632524</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4611-297918d64c4bb4cb3202958b1033138d9888180b04c7cf5d021f98e37117521f3</originalsourceid><addsrcrecordid>eNp1kU1rFTEUhoNYbLkW_4EEXCiUW_M5k2wEubQqtLjwYxsymYw3JTMZk8zoLPrfzXBrqQVXOTl58vKe9wDwAqNzjBB5O_eJnlP8BJwQxOkWI8mfPqiPwWlKNwghzFlNef0MHBOJqhpLcgJud6EfddTZzRbarnNGmwWGDubJ67yPoV-MG6AeWpidb93oYkil0YUI897CHK3OvR3y-sf-Hm106017eL2YMHqdeg2bMLsE3dBZk10YSgWN9rNNz8FRp32yp3fnBny7vPi6-7i9-vzh0-791dawCuMtkbXEoq2YYU3DTEMJIpKLBiNKMRWtFEJggRrETG063iKCOyksrTGueanpBrw76I5T09vWFIdRezUWszouKmin_n0Z3F79CLPiFeOiqovAmzuBGH5ONmXVu2Ss93qwYUoKS84rSjhhBX31CL0JUxzKeIqU3DEXgq3U6wNlSp4p2u7eDEZq3apat6rKeBvw8qH3e-7vDgtwdgB-OW-X_-mo79df1rT-AOBprKo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2290158844</pqid></control><display><type>article</type><title>Comparative efficacy of tulathromycin and tildipirosin for the treatment of experimental Mycoplasma bovis infection in calves</title><source>DOAJ Directory of Open Access Journals</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Wiley-Blackwell Open Access Titles</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Bartram, David J. ; Moyaert, Hilde ; Vanimisetti, Bindu H. ; Ramage, Clifford P. ; Reddick, David ; Stegemann, Michael R.</creator><creatorcontrib>Bartram, David J. ; Moyaert, Hilde ; Vanimisetti, Bindu H. ; Ramage, Clifford P. ; Reddick, David ; Stegemann, Michael R.</creatorcontrib><description>The objective of this negative controlled, blinded, randomised, parallel group study was to compare the efficacy of two injectable macrolide antimicrobials, tulathromycin and tildipirosin, administered by single subcutaneous injection at dose rates of 2.5 and 4.0 mg kg−1 bodyweight, respectively, in the treatment of an experimentally induced Mycoplasma bovis infection in calves. A total of 238 M. bovis‐negative calves were challenged on three consecutive days with M. bovis by endobronchial deposition. Post‐challenge, a total of 126 animals fulfilled the inclusion criteria and were randomly allocated to three treatment groups: tulathromycin, tildipirosin and saline. Clinical observations for signs of respiratory disease and injection site assessments were conducted daily for 14 days post‐treatment. The animals were then killed, the lungs were examined for evidence of lesions, and samples collected for bacterial isolation. Calves treated with tulathromycin had a lower percentage of lung with lesions (P = 0.0079), lower mortality (P = 0.0477), fewer days with depressed demeanour (P = 0.0486) and higher body weight (P = 0.0112) than calves administered tildipirosin.
The objective of this negative controlled, blinded, randomised, parallel group study was to compare the efficacy of two injectable macrolide antibiotics, tulathromycin and tildipirosin, administered by single subcutaneous injection at dose rates of 2.5 and 4.0 mg kg−1 bodyweight, respectively, in the treatment of an experimentally induced Mycoplasma bovis infection in calves. Calves treated with tulathromycin had a lower percentage of lung with lesions, (P = 0.0079), lower mortality (P = 0.0477), fewer days with depressed demeanour (P = 0.0486) and higher body weight (P = 0.0112) than cattle administered tildipirosin.</description><identifier>ISSN: 2053-1095</identifier><identifier>EISSN: 2053-1095</identifier><identifier>DOI: 10.1002/vms3.31</identifier><identifier>PMID: 29067192</identifier><language>eng</language><publisher>England: John Wiley & Sons, Inc</publisher><subject>Animals ; antimicrobial ; Antimicrobial agents ; Body weight ; bovine ; Cattle industry ; Disease prevention ; Infections ; Injection ; Laboratories ; macrolide ; Mycoplasma ; Mycoplasma bovis ; Original ; pneumonia ; Respiratory diseases ; Vaccines</subject><ispartof>Veterinary medicine and science, 2016-08, Vol.2 (3), p.170-178</ispartof><rights>2016 The Authors. Published by John Wiley & Sons Ltd.</rights><rights>2016. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4611-297918d64c4bb4cb3202958b1033138d9888180b04c7cf5d021f98e37117521f3</citedby><cites>FETCH-LOGICAL-c4611-297918d64c4bb4cb3202958b1033138d9888180b04c7cf5d021f98e37117521f3</cites><orcidid>0000-0001-9800-3346</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5645867/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5645867/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,861,882,1412,11543,27905,27906,45555,45556,46033,46457,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29067192$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bartram, David J.</creatorcontrib><creatorcontrib>Moyaert, Hilde</creatorcontrib><creatorcontrib>Vanimisetti, Bindu H.</creatorcontrib><creatorcontrib>Ramage, Clifford P.</creatorcontrib><creatorcontrib>Reddick, David</creatorcontrib><creatorcontrib>Stegemann, Michael R.</creatorcontrib><title>Comparative efficacy of tulathromycin and tildipirosin for the treatment of experimental Mycoplasma bovis infection in calves</title><title>Veterinary medicine and science</title><addtitle>Vet Med Sci</addtitle><description>The objective of this negative controlled, blinded, randomised, parallel group study was to compare the efficacy of two injectable macrolide antimicrobials, tulathromycin and tildipirosin, administered by single subcutaneous injection at dose rates of 2.5 and 4.0 mg kg−1 bodyweight, respectively, in the treatment of an experimentally induced Mycoplasma bovis infection in calves. A total of 238 M. bovis‐negative calves were challenged on three consecutive days with M. bovis by endobronchial deposition. Post‐challenge, a total of 126 animals fulfilled the inclusion criteria and were randomly allocated to three treatment groups: tulathromycin, tildipirosin and saline. Clinical observations for signs of respiratory disease and injection site assessments were conducted daily for 14 days post‐treatment. The animals were then killed, the lungs were examined for evidence of lesions, and samples collected for bacterial isolation. Calves treated with tulathromycin had a lower percentage of lung with lesions (P = 0.0079), lower mortality (P = 0.0477), fewer days with depressed demeanour (P = 0.0486) and higher body weight (P = 0.0112) than calves administered tildipirosin.
The objective of this negative controlled, blinded, randomised, parallel group study was to compare the efficacy of two injectable macrolide antibiotics, tulathromycin and tildipirosin, administered by single subcutaneous injection at dose rates of 2.5 and 4.0 mg kg−1 bodyweight, respectively, in the treatment of an experimentally induced Mycoplasma bovis infection in calves. Calves treated with tulathromycin had a lower percentage of lung with lesions, (P = 0.0079), lower mortality (P = 0.0477), fewer days with depressed demeanour (P = 0.0486) and higher body weight (P = 0.0112) than cattle administered tildipirosin.</description><subject>Animals</subject><subject>antimicrobial</subject><subject>Antimicrobial agents</subject><subject>Body weight</subject><subject>bovine</subject><subject>Cattle industry</subject><subject>Disease prevention</subject><subject>Infections</subject><subject>Injection</subject><subject>Laboratories</subject><subject>macrolide</subject><subject>Mycoplasma</subject><subject>Mycoplasma bovis</subject><subject>Original</subject><subject>pneumonia</subject><subject>Respiratory diseases</subject><subject>Vaccines</subject><issn>2053-1095</issn><issn>2053-1095</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kU1rFTEUhoNYbLkW_4EEXCiUW_M5k2wEubQqtLjwYxsymYw3JTMZk8zoLPrfzXBrqQVXOTl58vKe9wDwAqNzjBB5O_eJnlP8BJwQxOkWI8mfPqiPwWlKNwghzFlNef0MHBOJqhpLcgJud6EfddTZzRbarnNGmwWGDubJ67yPoV-MG6AeWpidb93oYkil0YUI897CHK3OvR3y-sf-Hm106017eL2YMHqdeg2bMLsE3dBZk10YSgWN9rNNz8FRp32yp3fnBny7vPi6-7i9-vzh0-791dawCuMtkbXEoq2YYU3DTEMJIpKLBiNKMRWtFEJggRrETG063iKCOyksrTGueanpBrw76I5T09vWFIdRezUWszouKmin_n0Z3F79CLPiFeOiqovAmzuBGH5ONmXVu2Ss93qwYUoKS84rSjhhBX31CL0JUxzKeIqU3DEXgq3U6wNlSp4p2u7eDEZq3apat6rKeBvw8qH3e-7vDgtwdgB-OW-X_-mo79df1rT-AOBprKo</recordid><startdate>201608</startdate><enddate>201608</enddate><creator>Bartram, David J.</creator><creator>Moyaert, Hilde</creator><creator>Vanimisetti, Bindu H.</creator><creator>Ramage, Clifford P.</creator><creator>Reddick, David</creator><creator>Stegemann, Michael R.</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9800-3346</orcidid></search><sort><creationdate>201608</creationdate><title>Comparative efficacy of tulathromycin and tildipirosin for the treatment of experimental Mycoplasma bovis infection in calves</title><author>Bartram, David J. ; Moyaert, Hilde ; Vanimisetti, Bindu H. ; Ramage, Clifford P. ; Reddick, David ; Stegemann, Michael R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4611-297918d64c4bb4cb3202958b1033138d9888180b04c7cf5d021f98e37117521f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Animals</topic><topic>antimicrobial</topic><topic>Antimicrobial agents</topic><topic>Body weight</topic><topic>bovine</topic><topic>Cattle industry</topic><topic>Disease prevention</topic><topic>Infections</topic><topic>Injection</topic><topic>Laboratories</topic><topic>macrolide</topic><topic>Mycoplasma</topic><topic>Mycoplasma bovis</topic><topic>Original</topic><topic>pneumonia</topic><topic>Respiratory diseases</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bartram, David J.</creatorcontrib><creatorcontrib>Moyaert, Hilde</creatorcontrib><creatorcontrib>Vanimisetti, Bindu H.</creatorcontrib><creatorcontrib>Ramage, Clifford P.</creatorcontrib><creatorcontrib>Reddick, David</creatorcontrib><creatorcontrib>Stegemann, Michael R.</creatorcontrib><collection>Wiley-Blackwell Open Access Titles</collection><collection>Wiley Free Content</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Veterinary medicine and science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bartram, David J.</au><au>Moyaert, Hilde</au><au>Vanimisetti, Bindu H.</au><au>Ramage, Clifford P.</au><au>Reddick, David</au><au>Stegemann, Michael R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparative efficacy of tulathromycin and tildipirosin for the treatment of experimental Mycoplasma bovis infection in calves</atitle><jtitle>Veterinary medicine and science</jtitle><addtitle>Vet Med Sci</addtitle><date>2016-08</date><risdate>2016</risdate><volume>2</volume><issue>3</issue><spage>170</spage><epage>178</epage><pages>170-178</pages><issn>2053-1095</issn><eissn>2053-1095</eissn><abstract>The objective of this negative controlled, blinded, randomised, parallel group study was to compare the efficacy of two injectable macrolide antimicrobials, tulathromycin and tildipirosin, administered by single subcutaneous injection at dose rates of 2.5 and 4.0 mg kg−1 bodyweight, respectively, in the treatment of an experimentally induced Mycoplasma bovis infection in calves. A total of 238 M. bovis‐negative calves were challenged on three consecutive days with M. bovis by endobronchial deposition. Post‐challenge, a total of 126 animals fulfilled the inclusion criteria and were randomly allocated to three treatment groups: tulathromycin, tildipirosin and saline. Clinical observations for signs of respiratory disease and injection site assessments were conducted daily for 14 days post‐treatment. The animals were then killed, the lungs were examined for evidence of lesions, and samples collected for bacterial isolation. Calves treated with tulathromycin had a lower percentage of lung with lesions (P = 0.0079), lower mortality (P = 0.0477), fewer days with depressed demeanour (P = 0.0486) and higher body weight (P = 0.0112) than calves administered tildipirosin.
The objective of this negative controlled, blinded, randomised, parallel group study was to compare the efficacy of two injectable macrolide antibiotics, tulathromycin and tildipirosin, administered by single subcutaneous injection at dose rates of 2.5 and 4.0 mg kg−1 bodyweight, respectively, in the treatment of an experimentally induced Mycoplasma bovis infection in calves. Calves treated with tulathromycin had a lower percentage of lung with lesions, (P = 0.0079), lower mortality (P = 0.0477), fewer days with depressed demeanour (P = 0.0486) and higher body weight (P = 0.0112) than cattle administered tildipirosin.</abstract><cop>England</cop><pub>John Wiley & Sons, Inc</pub><pmid>29067192</pmid><doi>10.1002/vms3.31</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-9800-3346</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2053-1095 |
| ispartof | Veterinary medicine and science, 2016-08, Vol.2 (3), p.170-178 |
| issn | 2053-1095 2053-1095 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5645867 |
| source | DOAJ Directory of Open Access Journals; Wiley Online Library Journals Frontfile Complete; Wiley-Blackwell Open Access Titles; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Animals antimicrobial Antimicrobial agents Body weight bovine Cattle industry Disease prevention Infections Injection Laboratories macrolide Mycoplasma Mycoplasma bovis Original pneumonia Respiratory diseases Vaccines |
| title | Comparative efficacy of tulathromycin and tildipirosin for the treatment of experimental Mycoplasma bovis infection in calves |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T03%3A23%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparative%20efficacy%20of%20tulathromycin%20and%20tildipirosin%20for%20the%20treatment%20of%20experimental%20Mycoplasma%20bovis%20infection%20in%20calves&rft.jtitle=Veterinary%20medicine%20and%20science&rft.au=Bartram,%20David%20J.&rft.date=2016-08&rft.volume=2&rft.issue=3&rft.spage=170&rft.epage=178&rft.pages=170-178&rft.issn=2053-1095&rft.eissn=2053-1095&rft_id=info:doi/10.1002/vms3.31&rft_dat=%3Cproquest_pubme%3E1955632524%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2290158844&rft_id=info:pmid/29067192&rfr_iscdi=true |